/* ─── Design Tokens ───────────────────────────────── */
:root {
–bg: #fdfdfd;
–navy: #00447c;
–accent: #088fc9;
–accent-lt: #e6f4fb;
/* BPC-157 palette — deep forest green / emerald */
–grn: #0f4c35;
–grn-mid: #1a7a50;
–grn-bright: #22a06b;
–grn-lt: #e8f5ef;
–grn-border: #8ecfb2;
/* Research domain colour strips */
–dom-a: #0f6b3b; /* Tissue remodelling */
–dom-b: #1a5276; /* Angiogenesis */
–dom-c: #5e3a7a; /* Neuro / CNS */
–dom-d: #7a5c1e; /* GI / cytoprotection*/
–text: #1a2535;
–muted: #5a6778;
–border: #d6dde6;
–success: #0a7c4e;
–warn-bg: #fff8e6;
–warn-border: #e6a817;
–radius: 6px;
–font-body: ‘DM Sans’, sans-serif;
–font-mono: ‘DM Mono’, monospace;
}
*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
body {
background: var(–bg);
color: var(–text);
font-family: var(–font-body);
font-size: 15.5px;
line-height: 1.72;
-webkit-font-smoothing: antialiased;
}
.bp-wrap { max-width: 860px; margin: 0 auto; padding: 0 20px; }
/* ─── Sections ────────────────────────────────────── */
section { padding: 52px 0; border-bottom: 1px solid var(–border); }
section:last-of-type { border-bottom: none; }
/* ─── Typography ──────────────────────────────────── */
h1, h2, h3 { font-weight: 600; letter-spacing: -0.02em; line-height: 1.25; }
h1 { font-size: clamp(1.65rem, 4vw, 2.2rem); color: var(–grn); margin-bottom: 16px; }
h2 { font-size: 1.35rem; color: var(–navy); margin-bottom: 18px; padding-bottom: 10px; border-bottom: 2px solid var(–grn-lt); }
h3 { font-size: 1.05rem; color: var(–navy); margin-bottom: 10px; }
p { margin-bottom: 14px; color: var(–text); }
p:last-child { margin-bottom: 0; }
/* ─── Chip ────────────────────────────────────────── */
.bp-chip {
display: inline-block;
background: var(–grn-lt);
color: var(–grn-mid);
font-size: 0.72rem;
font-weight: 600;
letter-spacing: 0.09em;
text-transform: uppercase;
padding: 4px 10px;
border-radius: 20px;
margin-bottom: 14px;
border: 1px solid var(–grn-border);
}
/* ─── Hero ────────────────────────────────────────── */
.bp-hero { padding: 56px 0 44px; border-bottom: 1px solid var(–border); }
.bp-hero-inner { display: flex; align-items: flex-start; gap: 36px; }
.bp-hero-text { flex: 1; }
/* BPC-157 purity badge — forest green gradient with sequence strip */
.bp-hero-badge {
flex-shrink: 0;
min-width: 150px;
border-radius: var(–radius);
overflow: hidden;
box-shadow: 0 4px 20px rgba(15,76,53,0.20);
}
.bp-badge-main {
background: linear-gradient(145deg, var(–grn) 0%, var(–grn-mid) 100%);
padding: 16px 16px 14px;
text-align: center;
}
.bp-badge-main .purity-val {
display: block;
font-size: 2rem;
font-weight: 600;
letter-spacing: -0.03em;
line-height: 1;
color: #fff;
}
.bp-badge-main .purity-label {
font-size: 0.68rem;
letter-spacing: 0.08em;
text-transform: uppercase;
color: rgba(255,255,255,0.60);
margin-top: 5px;
display: block;
}
.bp-badge-main .purity-sub {
font-size: 0.67rem;
color: rgba(255,255,255,0.45);
margin-top: 7px;
display: block;
border-top: 1px solid rgba(255,255,255,0.13);
padding-top: 7px;
}
/* Amino acid count strip */
.bp-badge-seq {
background: var(–grn);
padding: 9px 12px;
text-align: center;
border-top: 1px solid rgba(255,255,255,0.08);
}
.bp-badge-seq .seq-val {
display: block;
font-size: 1.1rem;
font-weight: 600;
color: #fff;
letter-spacing: -0.01em;
line-height: 1;
}
.bp-badge-seq .seq-label {
display: block;
font-size: 0.64rem;
letter-spacing: 0.08em;
text-transform: uppercase;
color: rgba(255,255,255,0.50);
margin-top: 3px;
}
@media (max-width: 580px) {
.bp-hero-inner { flex-direction: column; }
.bp-hero-badge { width: 100%; min-width: unset; display: flex; }
.bp-badge-main { flex: 2; }
.bp-badge-seq { flex: 1; border-top: none; border-left: 1px solid rgba(255,255,255,0.08); display: flex; flex-direction: column; justify-content: center; }
}
/* ─── Inline Trust Badge ──────────────────────────── */
.bp-inline-badge {
display: inline-flex; align-items: center; gap: 5px;
background: #eaf7ef; color: var(–success);
font-size: 0.75rem; font-weight: 600;
padding: 3px 9px; border-radius: 20px; letter-spacing: 0.05em;
}
.bp-inline-badge::before { content: ‘✓’; font-size: 0.7rem; }
/* ─── Key Features ────────────────────────────────── */
.bp-features {
list-style: none;
display: grid;
grid-template-columns: 1fr 1fr;
gap: 10px 24px;
margin-top: 6px;
}
@media (max-width: 520px) { .bp-features { grid-template-columns: 1fr; } }
.bp-features li {
display: flex; align-items: flex-start; gap: 10px;
padding: 12px 14px;
border: 1px solid var(–border); border-radius: var(–radius);
background: #fff; font-size: 0.88rem;
}
.bp-features li::before {
content: ”; display: inline-block; flex-shrink: 0;
width: 7px; height: 7px; border-radius: 50%;
background: var(–grn-bright); margin-top: 6px;
}
.bp-features li strong { color: var(–navy); font-weight: 500; }
/* ─── Research Domain Cards ───────────────────────── */
.bp-domain-grid {
display: grid;
grid-template-columns: 1fr 1fr;
gap: 14px;
margin: 20px 0 0;
}
@media (max-width: 560px) { .bp-domain-grid { grid-template-columns: 1fr; } }
.bp-domain-card { border-radius: var(–radius); overflow: hidden; border: 1px solid var(–border); }
.bp-domain-card-header {
padding: 9px 14px;
font-size: 0.72rem; font-weight: 700;
letter-spacing: 0.07em; text-transform: uppercase; color: #fff;
}
.bp-domain-card.tissue .bp-domain-card-header { background: var(–dom-a); }
.bp-domain-card.angio .bp-domain-card-header { background: var(–dom-b); }
.bp-domain-card.neuro .bp-domain-card-header { background: var(–dom-c); }
.bp-domain-card.gi .bp-domain-card-header { background: var(–dom-d); }
.bp-domain-card-body {
padding: 14px; background: #fff;
font-size: 0.84rem; color: var(–muted); line-height: 1.62;
}
/* ─── Context / Research Notes ────────────────────── */
.bp-context-note {
background: var(–accent-lt); border-left: 3px solid var(–accent);
border-radius: 0 var(–radius) var(–radius) 0;
padding: 14px 18px; margin: 18px 0 0; font-size: 0.86rem; color: var(–navy);
}
.bp-grn-note {
background: var(–grn-lt); border-left: 3px solid var(–grn-bright);
border-radius: 0 var(–radius) var(–radius) 0;
padding: 14px 18px; margin: 18px 0 0; font-size: 0.86rem; color: var(–grn);
}
.bp-grn-note strong { color: var(–grn-mid); }
/* ─── Specs Table ─────────────────────────────────── */
.bp-table-wrap { overflow-x: auto; margin-top: 4px; }
.bp-table { width: 100%; border-collapse: collapse; font-size: 0.875rem; }
.bp-table thead th {
background: var(–grn); color: #fff; text-align: left;
padding: 11px 16px; font-weight: 500; letter-spacing: 0.04em;
font-size: 0.78rem; text-transform: uppercase;
}
.bp-table tbody tr:nth-child(even) { background: var(–grn-lt); }
.bp-table tbody tr:nth-child(odd) { background: #fff; }
.bp-table tbody td {
padding: 11px 16px; border-bottom: 1px solid var(–border); vertical-align: top;
}
.bp-table tbody td:first-child {
font-weight: 500; color: var(–navy); white-space: nowrap; width: 38%;
}
.bp-table td code {
font-family: var(–font-mono); font-size: 0.83rem;
background: var(–grn-lt); padding: 1px 6px; border-radius: 3px;
color: var(–grn-mid); border: 1px solid var(–grn-border);
}
/* ─── QA Cards ────────────────────────────────────── */
.bp-qa-grid {
display: grid; grid-template-columns: repeat(auto-fit, minmax(190px, 1fr));
gap: 14px; margin-top: 8px;
}
.bp-qa-card { border: 1px solid var(–border); border-radius: var(–radius); padding: 18px 16px; background: #fff; }
.bp-qa-card .qa-icon { font-size: 1.4rem; margin-bottom: 8px; display: block; }
.bp-qa-card h3 { font-size: 0.88rem; margin-bottom: 6px; }
.bp-qa-card p { font-size: 0.82rem; color: var(–muted); margin-bottom: 0; }
/* ─── Storage Cards ───────────────────────────────── */
.bp-storage-grid {
display: grid; grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
gap: 12px; margin-top: 8px;
}
.bp-storage-card {
border-left: 3px solid var(–grn-bright);
padding: 14px 16px; background: #fff;
border-radius: 0 var(–radius) var(–radius) 0;
border-top: 1px solid var(–border);
border-right: 1px solid var(–border);
border-bottom: 1px solid var(–border);
}
.bp-storage-card h3 {
font-size: 0.8rem; letter-spacing: 0.06em; text-transform: uppercase;
color: var(–muted); margin-bottom: 5px;
}
.bp-storage-card p { font-size: 0.88rem; font-weight: 500; color: var(–navy); margin: 0; }
/* ─── Disclaimer ──────────────────────────────────── */
.bp-disclaimer {
background: var(–warn-bg); border: 1px solid var(–warn-border);
border-radius: var(–radius); padding: 20px 22px; margin-top: 4px;
}
.bp-disclaimer h2 {
border-bottom: none; padding-bottom: 0; font-size: 0.95rem; color: #7a4e00;
margin-bottom: 10px; text-transform: uppercase; letter-spacing: 0.06em;
}
.bp-disclaimer p { font-size: 0.84rem; color: #5a3b00; margin-bottom: 8px; }
/* ─── FAQ Accordion ───────────────────────────────── */
.bp-faq { margin-top: 6px; }
.bp-faq details {
border: 1px solid var(–border); border-radius: var(–radius);
margin-bottom: 8px; background: #fff; overflow: hidden;
}
.bp-faq details[open] {
box-shadow: 0 2px 12px rgba(15,76,53,0.09);
border-color: var(–grn-border);
}
.bp-faq summary {
cursor: pointer; padding: 15px 18px; font-weight: 500;
font-size: 0.93rem; color: var(–navy); list-style: none;
display: flex; align-items: center; justify-content: space-between;
gap: 12px; user-select: none;
}
.bp-faq summary::-webkit-details-marker { display: none; }
.bp-faq summary::after {
content: ‘+’; font-size: 1.2rem; font-weight: 300;
color: var(–grn-bright); flex-shrink: 0; line-height: 1;
}
.bp-faq details[open] summary::after { content: ‘−’; }
.bp-faq details p,
.bp-faq details ul {
padding: 0 18px 16px; font-size: 0.88rem; color: var(–muted); margin: 0;
}
.bp-faq details ul { padding-left: 34px; list-style: disc; }
.bp-faq details ul li { margin-bottom: 4px; }
.bp-faq details .faq-divider { height: 1px; background: var(–border); margin: 0 18px 14px; }
BPC-157
Body Protection Compound-157
BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence
of human gastric juice protein BPC, investigated extensively in preclinical research
models for its pleiotropic activity across gastrointestinal, musculoskeletal,
vascular, and neurological tissue systems. Baltic Peptides supplies BPC-157 as a
lyophilised research peptide at ≥99% analytical purity, independently verified by
third-party HPLC and mass spectrometry analysis.
This compound is made available exclusively for in vitro and preclinical
research purposes by qualified scientific investigators and licensed research institutions.
Third-Party Verified · COA Available · EU Dispatch
Analytical Purity
HPLC · Mass Spec Verified
Pentadecapeptide
Key Features
-
Purity — ≥99% by HPLC analysis
-
Form — Lyophilised powder, single-use vials
-
Storage (long-term) — −20 °C, desiccated, from light
-
Storage (short-term) — 2–8 °C, up to 4 weeks
-
Solubility — Sterile water, acetic acid solution, PBS
-
Classification — Research Use Only (RUO)
-
Testing — Independent third-party batch verification
-
Documentation — Certificate of Analysis (COA) per batch
Scientific Overview
Compound Background
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the amino
acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, first
characterised from the gastric juice protein BPC isolated in human gastric mucosa.
The compound is stable in gastric acid and exhibits a notable resistance to enzymatic
degradation, properties that have contributed to its utility as a research tool compound
across a wide range of in vivo and in vitro model systems. BPC-157 has no known
endogenous receptor characterised to date, and its mechanisms of action remain the
subject of active investigation, making it a subject of ongoing mechanistic pharmacology research.
The compound was first characterised and studied by a research group at the University
of Zagreb, with over 100 peer-reviewed publications in indexed journals examining its
behaviour in rodent model systems across multiple organ systems and tissue types. It has
not entered clinical development and has not been evaluated in registered human clinical
trials, positioning it firmly within the domain of preclinical and basic science research.
Preclinical Research Domains
BPC-157 research has been documented across several distinct biological domains in
preclinical model systems. The following represent the major areas of published
investigation, presented in a research context only:
ligament, bone, and muscle injuries. Studies have examined effects on fibroblast
proliferation, collagen organisation, and growth factor receptor expression
(including upregulation of VEGFR2 and FAK signalling) in injured tissue models.
and ischaemia models, associated with upregulation of VEGF expression and
promotion of new vessel formation. The compound has also been examined in models
of vascular anastomosis and blood pressure regulation.
injury, traumatic brain injury, and dopaminergic system modulation. Research
has documented effects on dopamine and serotonin neurotransmitter system behaviour
in rodent models of behavioural dysfunction.
activity centres on gastrointestinal mucosal healing. Rodent models of gastric
ulceration, IBD-like inflammation, and intestinal anastomosis have shown accelerated
repair responses associated with BPC-157 administration.
Proposed Mechanistic Pathways (Research Context)
BPC-157 does not act through a single well-characterised receptor pathway, which
distinguishes its mechanistic profile from classical peptide agonists. Preclinical
and in vitro data have implicated multiple upstream signalling interactions:
-
Nitric oxide (NO) system modulation: Multiple studies have proposed
involvement of the nitric oxide pathway in BPC-157’s observed vascular and
cytoprotective effects, with effects on both eNOS activity and NO-dependent
downstream signalling described in animal models. -
Growth factor receptor sensitisation: Research data suggest BPC-157
may upregulate expression of growth factor receptors — including VEGFR2 and EGFR —
in cell culture and in vivo models, potentially amplifying endogenous growth signal
responsiveness in damaged tissue environments. -
FAK–paxillin pathway: In vitro fibroblast studies have demonstrated
activation of focal adhesion kinase (FAK) and paxillin signalling associated with
BPC-157 exposure, suggesting a role in cytoskeletal organisation and cell migration
relevant to tissue repair models. -
Neurotransmitter system interactions: Rodent studies have reported
interactions with dopaminergic and serotonergic neurotransmission, including modulation
of dopamine release and receptor sensitivity in brain regions relevant to stress
and reward circuitry research models.
formally identified or characterised. The mechanistic pathways described above are
inferred from downstream signalling data in preclinical models and should be considered
working hypotheses rather than established mechanisms. This represents an active area
of basic pharmacology research.
preclinical animal model studies. No clinical trial data exist for BPC-157. The findings
described do not constitute therapeutic claims. This compound is supplied exclusively
for laboratory investigation by qualified researchers.
Technical Specifications
| Parameter | Specification |
|---|---|
| Compound Name | BPC-157 (Body Protection Compound-157) |
| Compound Class | Synthetic pentadecapeptide (15-mer) |
| Amino Acid Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1419.55 g/mol |
| CAS Number | 137525-51-0 |
| Purity | ≥99% (HPLC verified per batch) |
| Form | Lyophilised powder |
| Appearance | White to off-white powder |
| Solubility | Sterile water, 0.9% saline, dilute acetic acid (≥1 mg/mL); PBS pH 6.5–7.4 |
| Long-Term Storage | −20 °C, desiccated, protected from light |
| Short-Term Storage | 2–8 °C, sealed vial, up to 4 weeks |
| Reconstituted Stability | Up to 28 days at 2–8 °C; avoid freeze-thaw cycling |
| Research Classification | Research Use Only (RUO) |
Lab Testing & Quality Assurance
Every batch of BPC-157 research peptide supplied by Baltic Peptides undergoes a
rigorous multi-method analytical verification protocol prior to release. Quality
assurance is conducted independently of internal processes — third-party accredited
laboratories perform confirmatory testing on each production lot, ensuring both
analytical validity and full traceability of quality data.
HPLC Purity Analysis
Reverse-phase HPLC confirms ≥99% peptide purity with quantified impurity profiling per batch, including detection of truncated sequences and oxidised variants.
Mass Spectrometry
ESI-MS confirms the correct molecular mass of BPC-157, verifying sequence identity and ruling out amino acid substitution errors or peptide adducts.
Certificate of Analysis
A full, batch-specific COA documenting all analytical results, lot number, manufacturing and testing dates, and method references is issued per production lot and available on request.
Third-Party Verification
Independent accredited laboratory testing eliminates conflicts of interest and provides researchers with externally validated, auditable quality documentation for every batch.
Certificates of Analysis for current BPC-157 batches are available upon request
through the Baltic Peptides support portal. All lot-specific documentation is archived
and fully traceable from synthesis through to final release testing.
Storage & Handling Guidelines
BPC-157 is chemically stable in lyophilised form under appropriate storage conditions.
The peptide is notably resistant to enzymatic degradation in biological media, but
physical and oxidative stability in solution still requires standard peptide handling
precautions. The following conditions apply to all Baltic Peptides BPC-157
research-grade product:
Lyophilised (Unopened)
Store at −20 °C, desiccated. Stable for 24 months from manufacture date under recommended conditions.
Short-Term (Unopened)
2–8 °C acceptable for up to 4 weeks. Keep vial sealed; protect from ambient humidity and UV exposure.
Reconstituted Solution
Refrigerate at 2–8 °C. Stable for up to 28 days post-reconstitution. Avoid repeated freeze-thaw cycling.
Reconstitution Notes
Add solvent slowly along the vial wall. Swirl gently — do not vortex. If solubility is limited in water, dilute 0.1% acetic acid may be used as a vehicle.
⚠ Research Use Only — Important Notice
All products supplied by Baltic Peptides are designated exclusively for
in vitro research, preclinical investigation, and laboratory study
by qualified professionals operating within appropriately licensed or regulated
research environments.
BPC-157 is not approved for human or veterinary therapeutic use
by any national medicines regulatory authority, including the EMA, FDA, or MHRA.
It has not been evaluated in registered human clinical trials and is not intended
for self-administration, clinical application, or any use outside of legitimate
controlled scientific research.
By completing a purchase, the buyer confirms their status as a qualified researcher
and explicitly acknowledges the research-use-only classification of this compound.
Baltic Peptides assumes no liability for any use of this product beyond its stated
research designation.
Frequently Asked Questions
What is BPC-157 used for in scientific research?
BPC-157 is investigated as a preclinical tool compound across a range of tissue
and organ system models. Major documented areas of research include:
- Tendon, ligament, bone, and skeletal muscle healing models in rodents
- Gastrointestinal mucosal repair — gastric ulcer, colitis, and anastomosis models
- Angiogenesis and wound healing — VEGF pathway and vascular remodelling studies
- Peripheral and central nervous system injury models (crush injury, TBI)
- Dopaminergic and serotonergic neurotransmitter system behaviour in behavioural models
- Fibroblast biology, FAK–paxillin signalling, and cytoskeletal organisation in vitro
BPC-157 has not entered clinical trials and is not approved for any therapeutic
indication. It is supplied strictly for laboratory-based scientific investigation.
What makes BPC-157 stable compared to other research peptides?
BPC-157 displays an unusual degree of resistance to proteolytic degradation in
gastric acid and biological fluids, a property that has been observed across multiple
in vivo model systems and is attributed to its proline-rich sequence and specific
primary structure. This stability distinguishes it from many other linear peptides of
comparable length, which are typically rapidly degraded in the gastrointestinal
environment. In the context of oral route administration studies in rodent models,
this stability has allowed researchers to examine systemic effects following oral
delivery — a property not shared by most peptide tool compounds. Stability in solution
still requires standard refrigerated storage conditions as described in the handling
guidelines above.
How should BPC-157 peptide be stored after reconstitution?
Once reconstituted in sterile water, 0.9% saline, or dilute acetic acid solution,
BPC-157 solutions should be maintained at 2–8 °C and used within 28 days. Repeated
freeze-thaw cycling of reconstituted product should be avoided, as thermal cycling
may promote aggregation and reduce analytical homogeneity. Lyophilised vials that
have not yet been opened should be stored at −20 °C until the point of use, with
desiccation maintained to prevent moisture ingress into the vial.
What does ≥99% purity mean and why is it important for BPC-157 research?
A purity specification of ≥99% indicates that at least 99% of the material, by mass,
is confirmed to be the intact BPC-157 pentadecapeptide sequence, with the remaining
fraction comprising quantified impurities at or below 1% total. This is determined
by reverse-phase high-performance liquid chromatography (HPLC), with identity
confirmed orthogonally by electrospray ionisation mass spectrometry (ESI-MS).
For BPC-157 research specifically, impurity control is important because the compound
is frequently studied at low concentrations in cell culture and in vivo models where
even minor contaminants — such as truncated sequences or synthesis residuals — could
introduce biological noise or artefactual effects. High purity ensures that observed
results are attributable to the target compound rather than co-present impurities,
which is fundamental to reproducible and interpretable research outcomes.
Is a Certificate of Analysis available for BPC-157?
Yes. Baltic Peptides issues a batch-specific Certificate of Analysis for every
production lot of BPC-157 research peptide. Each COA documents HPLC purity data,
mass spectrometry identity confirmation, lot number, manufacturing and release
testing dates, and the analytical parameters applied by the testing laboratory.
Researchers may request the current batch COA via the Baltic Peptides support portal
prior to or following purchase. All historical lot documentation is archived and
available upon inquiry.
What solvent should be used to reconstitute BPC-157 for laboratory use?
BPC-157 is soluble in sterile water for injection, 0.9% physiological saline, and
phosphate-buffered saline (pH 6.5–7.4), typically achieving working concentrations
of ≥1 mg/mL. If solubility challenges are encountered at higher concentrations,
dilute aqueous acetic acid (0.1–1% v/v) is an effective alternative vehicle that
improves dissolution without compromising peptide integrity, and should be assessed
for compatibility with the specific downstream assay format. In all cases, solvent
should be added slowly along the vial wall and the solution swirled gently — not
vortexed — to achieve complete dissolution without introducing air or mechanical stress.
What are the shipping and packaging conditions for BPC-157 orders from Baltic Peptides?
BPC-157 is dispatched in lyophilised form, conferring inherent thermal stability
advantages over liquid peptide preparations during transit. All Baltic Peptides orders
are packaged with temperature-protective materials appropriate for lyophilised peptide
compounds. Baltic Peptides dispatches from within the EU, providing shorter transit
times and reduced customs exposure for European research institutions. Cold-chain
insulated packaging is available upon request for orders requiring additional
temperature assurance. Each shipment includes product labelling stating lot number,
storage conditions, and research-use-only classification. Expedited shipping options
are available for time-sensitive research requirements on request.
Stavros P. — UK (verified owner) –
delivery was quicker than I expected. will order again for sure
Baptiste C. — Romania (verified owner) –
ordered on a monday, arrived by friday. great
Adrian F. — Sweden (verified owner) –
no complaints at all. arrived on time and in good condition
Björn L. — Germany (verified owner) –
great products and speedy delivery. recommended
Krzysztof L. — Sweden (verified owner) –
delivery was quicker than I expected. will order again for sure
Stefan R. — Finland (verified owner) –
arrived in a few days, packaging was solid. 5 stars